Abstract:Abstract Background Biological drugs has revolutionized the management of inflammatory bowel disease (IBD). However, its use has led to a significant increase in cost that has strained health systems. Biosimilars will reduce cost related to treatment, allowing access to a greater proportion of patients. However, data on the efficacy and safety of the various ADA biosimilars in IBD patients "naive" to biologics remains scarce. Methods We performed an observational cohort study in 9 hospitals in Galicia. All patients with IBD naïve to biologics who started ADA biosimilar between November 2018 and January 2022 for control of their disease were enrolled. The primary endpoints were efficacy defined as clinical remission at week 8 and long term efficacy defined as persistence on drug treatment at the end of follow-up. The other co-primary endpoint was to determine the incidence of adverse events that lead to suspension or discontinuation of the drug or hospitalization of the patient Results 384 patients (95 CU; 283 CD) with a median age of 47 (34-60) years and a median disease duration of 3.4 (0.8-10.0) years before starting treatment were included. After induction (at 8 weeks) 63.7 % of patients were in clinical remission and 85.0 % achieved clinical response. At this time of follow-up, 14 patients (4.9 %) discontinued treatment mainly due to primary non-response (PNR) (57.1 %) and adverse events (42.9 %). In total, 112 patients discontinued treatment during follow-up (Figure 1). The main reasons for stopping therapy were adverse events (32.1 %), PNR (30.4 %) and secondary loss of response (37.5 %). Clinical remission was maintained in 60.9 % of patients, after a median follow-up of 18 (12-24) months. Drug persistence shown by Kaplan-Meier survival curves were significantly higher in CD patients (p = 0.007) and in the group of patients treated with immunomodulators (IMM) (p = 0.001). Additionally, the rates of clinical remission and clinical response were higher in CD patients and in IMM-treated patients (Table 1). Adalimumab levels were also measured during follow-up, showing a median of 11 (6.8-14) μg/mL. Significantly, drug persistence was higher in patients with adalimumab levels ≥ 7 μg/mL at week 4 (p < 0.001). Regarding treatment safety in this population, adverse events that required treatment suspension or discontinuation were reported in 36 patients. Conclusion Adalimumab biosimilars in usual clinical practice are safe and effective in inducing and maintaining remission in Galician patients with IBD. Drug persistence was significantly higher in patients with CD, treated with IMM and with post-induction ADA levels ≥ 7 μg/mL.

Clinical experience of using biosimilars in Crohn's disease and their effectiveness

An International Survey

Practical Management of Biosimilar Use in Inflammatory Bowel Disease (IBD): A Global Survey and an International Delphi Consensus

Adalimumab biosimilars in the therapy of Crohn´s disease and ulcerative colitis: Prospective multicentric clinical monitoring

Biosimilars in IBD: What Every Clinician Needs to Know

P888 Effectiveness and safety of Adalimumab Biosimilars in Bio-naive patients with Inflammatory Bowel Disease: The Galician experience

Outcomes of the use of infliximab biosimilars in rheumatology and gastroenterology clinics

An Update on Anti-TNF Biosimilar Switching-Real-World Clinical Effectiveness and Safety

Clinical Guide to Navigating the Landscape of Biosimilars for Inflammatory Bowel Disease

ARE WE READY FOR MULTIPLE SWITCHES BETWEEN REFERENCE PRODUCTS AND BIOSIMILARS?

Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD)

Biosimilars in Pediatric IBD: Updated Considerations for Disease Management

Efficacy and safety of biosimilar versus originator infliximab in patients with inflammatory bowel disease: A real-world cohort analysis

Under the Umbrella of Clinical Pharmacology: Inflammatory Bowel Disease, Infliximab and Adalimumab, and a Bridge to an Era of Biosimilars

The Efficacy, Safety, and Persistence of Therapy after Non-Medical Switching from an Originator Adalimumab in Inflammatory Bowel Disease: Real-Life Experience from Two Tertiary Centres

P938 Effectiveness and safety of switching from original infliximab to GP1111 biosimilar in inflammatory bowel diseases – prospective, cohort study

Clinical outcomes and cost savings of a nonmedical switch to a biosimilar in children/young adults with inflammatory bowel disease

Efficacy of Infliximab Biosimilar for Maintenance Therapy in Pediatric Inflammatory Bowel Disease Following Infliximab Originator

Efficacy and Safety of Adalimumab Biosimilar GP2017 in Patients with Inflammatory Bowel Disease

ECCO position statement: The use of biosimilar medicines in the treatment of inflammatory bowel disease (IBD)

Multiple infliximab biosimilar switches appear to be safe and effective in a real-world inflammatory bowel disease cohort